Does local drug delivery still hold therapeutic promise for brain cancer? A systematic review

• Published in: Journal of controlled release Vol. 337; pp. 296 - 305
• Main Authors: Bastiancich, C., Bozzato, E., Henley, I., Newland, B.
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 10.09.2021; Elsevier
• Subjects: Drug delivery systems; Glioblastoma multiforme; Life Sciences; Local delivery; Meta-analysis; Preclinical models; Systematic review; Local delivery; Systematic review; Drug delivery systems; Glioblastoma multiforme; Preclinical models; Meta-analysis
• ISSN: 0168-3659; 1873-4995
• DOI: 10.1016/j.jconrel.2021.07.031

Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. Despite the gold standard treatment combining surgical resection, radiation and adjuvant plus concomitant chemotherapy with the alkylating agent temozolomide (TMZ), the prognosis remains poor (5-year survival rate < 10%). Over the last three decades, a vast array of drug delivery systems (DDS) have been developed for the local treatment of GBM, with the majority of the characterization being undertaken in pre-clinical models. We aimed to gain an overview of the potential efficacy of such local delivery systems in comparison to the systemic drug administration. In this paper, a systematic search of Pubmed, Web of Science, and Scopus was performed using pre-determined search terms. Studies were assessed for eligibility based on specific inclusion and exclusion criteria. A total of fifteen publications were included for analysis of local vs systemic group median survival, tumor volume and adverse events, with five brought forward for a meta-analysis. The majority of studies showed local delivery to be more efficacious than systemic administration, regardless of the drug, animal model, type of DDS used, or duration of the study. The meta-analysis also showed that the mean difference between median survival ratios was statistically significantly in favor of local delivery. Preclinical evidence shows that there is a firm rationale for further developing DDS for local therapeutic delivery to GBM and other brain cancers. [Display omitted] •Gliadel wafers for glioblastoma have achieved limited success in the clinic.•New drug delivery systems are being designed to overcome current drawbacks.•Preclinical data from local systems is compared against systemic administration.•Local delivery gives a higher median survival time than systemic administration.•This data provides a firm rationale for development of local drug delivery devices.